Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	IgG receptor activity	FCGR2C FCGR2A FCGR2B	2.18e-05	7	173	3	GO:0019770
GeneOntologyMolecularFunction	IgG binding	FCGR2C FCGR2A FCGR2B	1.00e-04	11	173	3	GO:0019864
GeneOntologyMolecularFunction	immunoglobulin receptor activity	FCGR2C FCGR2A FCGR2B	2.17e-04	14	173	3	GO:0019763
Domain	WD40_repeat_dom	ATG16L1 WDR33 UBR4 EIPR1 ARHGEF17 EML3 WDR59 MAPK8IP3 FZR1 WDR87 DNAI2 BUB3 WDR77 RIC1	6.79e-07	297	172	14	IPR017986
Domain	-	ATG16L1 WDR33 EIPR1 ARHGEF17 EML3 WDR59 MAPK8IP3 FZR1 WDR87 WDCP DNAI2 BUB3 WDR77 RIC1	2.62e-06	333	172	14	2.130.10.10
Domain	WD40/YVTN_repeat-like_dom	ATG16L1 WDR33 EIPR1 ARHGEF17 EML3 WDR59 MAPK8IP3 FZR1 WDR87 WDCP DNAI2 BUB3 WDR77 RIC1	2.81e-06	335	172	14	IPR015943
Domain	Sushi	PAPPA2 CSMD2 CSMD3 SVEP1 NCAN CSMD1	8.01e-06	52	172	6	PF00084
Domain	CCP	PAPPA2 CSMD2 CSMD3 SVEP1 NCAN CSMD1	1.00e-05	54	172	6	SM00032
Domain	WD_REPEATS_1	ATG16L1 WDR33 EIPR1 EML3 WDR59 FZR1 WDR87 WDCP DNAI2 BUB3 WDR77 RIC1	1.07e-05	278	172	12	PS00678
Domain	WD_REPEATS_2	ATG16L1 WDR33 EIPR1 EML3 WDR59 FZR1 WDR87 WDCP DNAI2 BUB3 WDR77 RIC1	1.11e-05	279	172	12	PS50082
Domain	WD_REPEATS_REGION	ATG16L1 WDR33 EIPR1 EML3 WDR59 FZR1 WDR87 WDCP DNAI2 BUB3 WDR77 RIC1	1.11e-05	279	172	12	PS50294
Domain	SUSHI	PAPPA2 CSMD2 CSMD3 SVEP1 NCAN CSMD1	1.24e-05	56	172	6	PS50923
Domain	Sushi_SCR_CCP_dom	PAPPA2 CSMD2 CSMD3 SVEP1 NCAN CSMD1	1.37e-05	57	172	6	IPR000436
Domain	-	PAPPA2 SVEP1 THBS2 CNTNAP5 LMAN1 CELSR3 CELSR2	2.78e-05	95	172	7	2.60.120.200
Domain	NLGN4	NLGN4Y NLGN4X	8.43e-05	2	172	2	IPR030025
Domain	EGF_CA	TENM2 SVEP1 THBS2 HMCN2 CELSR3 CELSR2 NCAN	1.37e-04	122	172	7	SM00179
Domain	WD40	ATG16L1 WDR33 EIPR1 EML3 WDR59 FZR1 WDR87 DNAI2 BUB3 WDR77	1.48e-04	259	172	10	PF00400
Domain	EGF-like_Ca-bd_dom	TENM2 SVEP1 THBS2 HMCN2 CELSR3 CELSR2 NCAN	1.52e-04	124	172	7	IPR001881
Domain	WD40	ATG16L1 WDR33 EIPR1 EML3 WDR59 FZR1 WDR87 DNAI2 BUB3 WDR77	1.95e-04	268	172	10	SM00320
Domain	WD40_repeat	ATG16L1 WDR33 EIPR1 EML3 WDR59 FZR1 WDR87 DNAI2 BUB3 WDR77	2.20e-04	272	172	10	IPR001680
Domain	EGF	TENM2 SVEP1 THBS2 CNTNAP5 CELSR3 CELSR2 NCAN TENM1 BRINP2	3.37e-04	235	172	9	SM00181
Domain	EGF_3	TENM2 SVEP1 THBS2 CNTNAP5 HMCN2 CELSR3 CELSR2 NCAN TENM1	3.37e-04	235	172	9	PS50026
Domain	Tox-GHH_dom	TENM2 TENM1	5.00e-04	4	172	2	IPR028916
Domain	TF_POU_3	POU3F1 POU3F2	5.00e-04	4	172	2	IPR016362
Domain	Tox-GHH	TENM2 TENM1	5.00e-04	4	172	2	PF15636
Domain	Ten_N	TENM2 TENM1	5.00e-04	4	172	2	IPR009471
Domain	Ten_N	TENM2 TENM1	5.00e-04	4	172	2	PF06484
Domain	TENEURIN_N	TENM2 TENM1	5.00e-04	4	172	2	PS51361
Domain	EGF-like_dom	TENM2 SVEP1 THBS2 CNTNAP5 HMCN2 CELSR3 CELSR2 NCAN TENM1	5.14e-04	249	172	9	IPR000742
Domain	EGF_1	TENM2 SVEP1 THBS2 CNTNAP5 HMCN2 CELSR3 CELSR2 NCAN TENM1	6.09e-04	255	172	9	PS00022
Domain	EGF_2	TENM2 SVEP1 THBS2 CNTNAP5 HMCN2 CELSR3 CELSR2 NCAN TENM1	8.01e-04	265	172	9	PS01186
Domain	YD	TENM2 TENM1	8.28e-04	5	172	2	IPR006530
Domain	Nlgn	NLGN4Y NLGN4X	8.28e-04	5	172	2	IPR000460
Domain	Lectin_C	CLEC6A PKD1L3 NCAN KLRC2 KLRC3	1.07e-03	84	172	5	PF00059
Domain	C-type_lectin-like	CLEC6A PKD1L3 NCAN KLRC2 KLRC3	1.19e-03	86	172	5	IPR001304
Domain	Ank	ANKK1 GIT1 ASB11 ASB9 ASB3 ANKDD1A PLA2G6 ZDHHC13	1.27e-03	228	172	8	PF00023
Domain	Arm_3	KPNA4 KPNA2	1.72e-03	7	172	2	PF16186
Domain	Importing_su_alpha	KPNA4 KPNA2	1.72e-03	7	172	2	IPR024931
Domain	IBB	KPNA4 KPNA2	1.72e-03	7	172	2	PF01749
Domain	Rab_bind	RGPD2 RGPD1	1.72e-03	7	172	2	PF16704
Domain	GCC2_Rab_bind	RGPD2 RGPD1	1.72e-03	7	172	2	IPR032023
Domain	Znf_GRF	ZCCHC4 APEX2	1.72e-03	7	172	2	IPR010666
Domain	Arm_3	KPNA4 KPNA2	1.72e-03	7	172	2	IPR032413
Domain	zf-GRF	ZCCHC4 APEX2	1.72e-03	7	172	2	PF06839
Domain	Ser/Thr_kinase_AS	ANKK1 CAMK1D RPS6KA1 CAMK1G TAOK2 MAST4 TBK1 MAPKAPK3 WEE2 MAP3K19	1.78e-03	357	172	10	IPR008271
Domain	S_TKc	ANKK1 CAMK1D RPS6KA1 CAMK1G TAOK2 MAST4 TBK1 MAPKAPK3 WEE2 MAP3K19	1.86e-03	359	172	10	SM00220
Domain	PROTEIN_KINASE_ST	ANKK1 CAMK1D RPS6KA1 CAMK1G TAOK2 MAST4 TBK1 MAPKAPK3 WEE2 MAP3K19	1.98e-03	362	172	10	PS00108
Domain	Laminin_G	THBS2 CNTNAP5 CELSR3 CELSR2	2.00e-03	58	172	4	IPR001791
Domain	-	CLEC6A PKD1L3 NCAN KLRC2 KLRC3	2.04e-03	97	172	5	3.10.100.10
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	GADD45B TBKBP1 UBR4 RTTN FRYL ZNF236 RNF43 EML3 WDR59 MAPK8IP3 TRAK1 TAOK2 NHSL1 PLEKHG1 FZR1 PSME4 CELSR3 CELSR2 ADAMTSL5 PLA2G6 ATG9A RIC1	5.49e-08	1105	177	22	35748872
Pubmed	Identification of two new members of the CSMD gene family.	CSMD2 CSMD3 CSMD1	1.30e-07	3	177	3	12906867
Pubmed	Fcgr2b and Fcgr3 are the major genetic factors for cartilage antibody-induced arthritis, overriding the effect of Hc encoding complement C5.	FCGR2A FCGR2B C5	1.30e-07	3	177	3	38314895
Pubmed	Nonallelic homologous recombination of the FCGR2/3 locus results in copy number variation and novel chimeric FCGR2 genes with aberrant functional expression.	FCGR2C FCGR2A FCGR2B	1.30e-07	3	177	3	26133275
Pubmed	Characterization of the murine IgG Fc receptor III and IIB gene promoters: a single two-nucleotide difference determines their inverse responsiveness to C5a.	FCGR2A FCGR2B C5	1.30e-07	3	177	3	17956862
Pubmed	Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes.	FCGR2A FCGR2B C5	1.30e-07	3	177	3	11433381
Pubmed	Functional Fcgamma receptor polymorphisms are associated with human allergy.	FCGR2C FCGR2A FCGR2B	1.30e-07	3	177	3	24586589
Pubmed	Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice.	COL7A1 FCGR2A FCGR2B	5.16e-07	4	177	3	16920988
Pubmed	Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B.	FCGR2C FCGR2A FCGR2B	1.29e-06	5	177	3	19309690
Pubmed	SNPs of Fc-gamma receptor genes and chronic periodontitis.	FCGR2C FCGR2A FCGR2B	1.29e-06	5	177	3	20439936
Pubmed	Copy number, linkage disequilibrium and disease association in the FCGR locus.	FCGR2C FCGR2A FCGR2B	1.29e-06	5	177	3	20508037
Pubmed	Clearance of Bordetella parapertussis from the lower respiratory tract requires humoral and cellular immunity.	FCGR2A FCGR2B C5	2.56e-06	6	177	3	16177324
Pubmed	The complex mechanism of antibody-mediated clearance of Bordetella from the lungs requires TLR4.	FCGR2A FCGR2B C5	4.47e-06	7	177	3	16301658
Pubmed	Anti-Ganglioside Antibodies Induce Nodal and Axonal Injury via Fcγ Receptor-Mediated Inflammation.	FCGR2A FCGR2B C5	7.12e-06	8	177	3	25926454
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	RGPD2 NRCAM GIT1 UBR4 RGPD1 BCL11A TMEM132B TENM2 MAPK8IP3 TAOK2 CNTNAP5 CELSR2 GPR158 TBK1 NCAN BUB3 HSPA9	9.54e-06	963	177	17	28671696
Pubmed	Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2.	FCGR2A FCGR2B C5	1.06e-05	9	177	3	29599777
Pubmed	Prediction of the coding sequences of unidentified human genes. XXI. The complete sequences of 60 new cDNA clones from brain which code for large proteins.	CSMD2 CSMD3 TMEM132B WDR59 CSMD1	1.79e-05	63	177	5	11572484
Pubmed	Functional analysis of Asb-1 using genetic modification in mice.	ASB11 ASB9 ASB3	2.08e-05	11	177	3	11509662
Pubmed	Both FcgammaRIV and FcgammaRIII are essential receptors mediating type II and type III autoimmune responses via FcRgamma-LAT-dependent generation of C5a.	FCGR2A FCGR2B C5	2.08e-05	11	177	3	19795417
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	KCNH8 TBKBP1 NLGN4Y GPATCH2 FRYL POMT1 EIPR1 ZNF236 TRIP13 MEF2A MAPK8IP3 EGFR GPR158 TBK1 PLA2G6 CSMD1 PATJ ZDHHC13 RIC1 DOP1A RAVER1	2.49e-05	1489	177	21	28611215
Pubmed	Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection.	FCGR2A FCGR2B	2.58e-05	2	177	2	23616574
Pubmed	FcgammaRIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan.	FCGR2A FCGR2B	2.58e-05	2	177	2	19284648
Pubmed	Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity.	FCGR2A FCGR2B	2.58e-05	2	177	2	17548594
Pubmed	Intraperitoneal Immunization with Cry1Ac Protoxin from Bacillus thuringiensis Provokes Upregulation of Fc-Gamma-II/and Fc-Gamma-III Receptors Associated with IgG in the Intestinal Epithelium of Mice.	FCGR2A FCGR2B	2.58e-05	2	177	2	25904149
Pubmed	Development of self-reactive germinal center B cells and plasma cells in autoimmune Fc gammaRIIB-deficient mice.	FCGR2A FCGR2B	2.58e-05	2	177	2	21078890
Pubmed	FcγRIIB is a T cell checkpoint in antitumor immunity.	FCGR2A FCGR2B	2.58e-05	2	177	2	33616086
Pubmed	Etanercept prevents TNF-α mediated mandibular bone loss in FcγRIIb-/- lupus model.	FCGR2A FCGR2B	2.58e-05	2	177	2	33861790
Pubmed	FcgammaRIIb inhibits allergic lung inflammation in a murine model of allergic asthma.	FCGR2A FCGR2B	2.58e-05	2	177	2	20179765
Pubmed	Respiratory syncytial virus persistence in macrophages upregulates Fcgamma receptors expression.	FCGR2A FCGR2B	2.58e-05	2	177	2	24509813
Pubmed	Antigen-Specific IgG ameliorates allergic airway inflammation via Fcγ receptor IIB on dendritic cells.	FCGR2A FCGR2B	2.58e-05	2	177	2	21477339
Pubmed	Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.	FCGR2A FCGR2B	2.58e-05	2	177	2	32684632
Pubmed	Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease.	KCP BMP7	2.58e-05	2	177	2	15793581
Pubmed	Opposite regulation of type II and III receptors for immunoglobulin G in mouse glomerular mesangial cells and in the induction of anti-glomerular basement membrane (GBM) nephritis.	FCGR2A FCGR2B	2.58e-05	2	177	2	11983693
Pubmed	Acute Kidney Injury Induced Lupus Exacerbation Through the Enhanced Neutrophil Extracellular Traps (and Apoptosis) in Fcgr2b Deficient Lupus Mice With Renal Ischemia Reperfusion Injury.	FCGR2A FCGR2B	2.58e-05	2	177	2	34248948
Pubmed	Negative regulation of c-kit-mediated cell proliferation by Fc gamma RIIB.	FCGR2A FCGR2B	2.58e-05	2	177	2	10201978
Pubmed	Antigen-induced oligomerization of the B cell receptor is an early target of Fc gamma RIIB inhibition.	FCGR2A FCGR2B	2.58e-05	2	177	2	20083655
Pubmed	Human IgG Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and IgG-transporting placental epithelium.	FCGR2C FCGR2B	2.58e-05	2	177	2	2531080
Pubmed	Genomic organization of mouse Fc gamma receptor genes.	FCGR2A FCGR2B	2.58e-05	2	177	2	2138787
Pubmed	Fc receptors: rubor redux.	FCGR2A FCGR2B	2.58e-05	2	177	2	8069908
Pubmed	Genetic control of T-cell proliferative response in mice linked to chromosomes 11 and 15.	FCGR2A FCGR2B	2.58e-05	2	177	2	8824160
Pubmed	Regulation of allograft survival by inhibitory FcγRIIb signaling.	FCGR2A FCGR2B	2.58e-05	2	177	2	23150718
Pubmed	FcγRIIIA Negatively Impacts Humoral Immune Responses but Not Overall Lung Inflammation in an Ovalbumin-Induced Allergic Asthma Mouse Model.	FCGR2A FCGR2B	2.58e-05	2	177	2	29597194
Pubmed	Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus.	FCGR2A FCGR2B	2.58e-05	2	177	2	21357255
Pubmed	Association of FcγRIIB and FcγRIIA R131H gene polymorphisms with renal involvement in Egyptian systemic lupus erythematosus patients.	FCGR2A FCGR2B	2.58e-05	2	177	2	24366619
Pubmed	Differences in endocytosis mediated by FcγRIIA and FcγRIIB2.	FCGR2A FCGR2B	2.58e-05	2	177	2	21945020
Pubmed	Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody.	FCGR2A FCGR2B	2.58e-05	2	177	2	16925577
Pubmed	FcγRIIb on liver sinusoidal endothelium clears small immune complexes.	FCGR2A FCGR2B	2.58e-05	2	177	2	23053513
Pubmed	A complementary DNA clone for a macrophage-lymphocyte Fc receptor.	FCGR2A FCGR2B	2.58e-05	2	177	2	3024012
Pubmed	Human rhinovirus type 2-antibody complexes enter and infect cells via Fc-gamma receptor IIB1.	FCGR2A FCGR2B	2.58e-05	2	177	2	14990693
Pubmed	Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease.	FCGR2A FCGR2B	2.58e-05	2	177	2	10704470
Pubmed	Biochemical characterization of murine lymphoid alloantigen Ly-m20.2, a cell surface marker controlled by a gene linked to the Mls locus.	FCGR2A FCGR2B	2.58e-05	2	177	2	3161943
Pubmed	Lipopolysaccharide Impedes Bone Repair in FcγRIIB-Deficient Mice.	FCGR2A FCGR2B	2.58e-05	2	177	2	38069267
Pubmed	Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII.	FCGR2A FCGR2B	2.58e-05	2	177	2	10704418
Pubmed	Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations.	EGFR MLH1	2.58e-05	2	177	2	24205245
Pubmed	Plasmodium curtails autoimmune nephritis via lasting bone marrow alterations, independent of hemozoin accumulation.	FCGR2A FCGR2B	2.58e-05	2	177	2	37539049
Pubmed	Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.	FCGR2A FCGR2B	2.58e-05	2	177	2	23897982
Pubmed	CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.	FCGR2A FCGR2B	2.58e-05	2	177	2	16757681
Pubmed	FcγRIIb attenuates TLR4‑mediated NF‑κB signaling in B cells.	FCGR2A FCGR2B	2.58e-05	2	177	2	28849025
Pubmed	Fc receptor beta chain deficiency exacerbates murine arthritis in the anti-type II collagen antibody-induced experimental model.	FCGR2A FCGR2B	2.58e-05	2	177	2	23053716
Pubmed	Fc gamma RIIB regulates nasal and oral tolerance: a role for dendritic cells.	FCGR2A FCGR2B	2.58e-05	2	177	2	15843524
Pubmed	Chromosomal localization of Celsr2 and Celsr3 in the mouse; Celsr3 is a candidate for the tippy (tip) lethal mutant on chromosome 9.	CELSR3 CELSR2	2.58e-05	2	177	2	10790539
Pubmed	Lupus nephritis progression in FcγRIIB-/-yaa mice is associated with early development of glomerular electron dense deposits and loss of renal DNase I in severe disease.	FCGR2A FCGR2B	2.58e-05	2	177	2	29190833
Pubmed	Development of an autism severity score for mice using Nlgn4 null mutants as a construct-valid model of heritable monogenic autism.	NLGN4Y NLGN4X	2.58e-05	2	177	2	23183221
Pubmed	Identification of a high affinity FcgammaRIIA-binding peptide that distinguishes FcgammaRIIA from FcgammaRIIB and exploits FcgammaRIIA-mediated phagocytosis and degradation.	FCGR2A FCGR2B	2.58e-05	2	177	2	18957413
Pubmed	Juvenile manifestation of ultrasound communication deficits in the neuroligin-4 null mutant mouse model of autism.	NLGN4Y NLGN4X	2.58e-05	2	177	2	24855039
Pubmed	Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice.	FCGR2A FCGR2B	2.58e-05	2	177	2	19644866
Pubmed	Comment on "The inhibiting Fc receptor for IgG, FcgammaRIIB, is a modifier of autoimmune susceptibility".	FCGR2A FCGR2B	2.58e-05	2	177	2	21969314
Pubmed	Immunoglobulin E plays an immunoregulatory role in lupus.	FCGR2A FCGR2B	2.58e-05	2	177	2	25267791
Pubmed	FcγRIIB regulates T-cell autoreactivity, ANCA production, and neutrophil activation to suppress anti-myeloperoxidase glomerulonephritis.	FCGR2A FCGR2B	2.58e-05	2	177	2	24869670
Pubmed	Lupus-Associated Immune Complexes Activate Human Neutrophils in an FcγRIIA-Dependent but TLR-Independent Response.	FCGR2A FCGR2B	2.58e-05	2	177	2	30610165
Pubmed	Fc receptors.	FCGR2A FCGR2B	2.58e-05	2	177	2	1910686
Pubmed	Sex-specific microglia state in the Neuroligin-4 knock-out mouse model of autism spectrum disorder.	NLGN4Y NLGN4X	2.58e-05	2	177	2	37001827
Pubmed	Susceptibility quantitative trait loci for pathogenic leucocytosis in SCG/Kj mice, a spontaneously occurring crescentic glomerulonephritis and vasculitis model.	FCGR2A FCGR2B	2.58e-05	2	177	2	24654803
Pubmed	An alloantigen selective for B cells: Ly-17.1.	FCGR2A FCGR2B	2.58e-05	2	177	2	6974691
Pubmed	Functional Role of FcγRIIB in the Regulation of Mesenchymal Stem Cell Function.	FCGR2A FCGR2B	2.58e-05	2	177	2	26941575
Pubmed	Differential role of three major New Zealand Black-derived loci linked with Yaa-induced murine lupus nephritis.	FCGR2A FCGR2B	2.58e-05	2	177	2	15634937
Pubmed	Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus.	FCGR2A FCGR2B	2.58e-05	2	177	2	10508186
Pubmed	Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells.	FCGR2A FCGR2B	2.58e-05	2	177	2	26451966
Pubmed	Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-antibody complexes.	FCGR2A FCGR2B	2.58e-05	2	177	2	17142741
Pubmed	Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.	FCGR2A FCGR2B	2.58e-05	2	177	2	25568316
Pubmed	A lupus-suppressor BALB/c locus restricts IgG2 autoantibodies without altering intrinsic B cell-tolerance mechanisms.	FCGR2A FCGR2B	2.58e-05	2	177	2	18322187
Pubmed	Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease.	FCGR2A FCGR2B	2.58e-05	2	177	2	17322382
Pubmed	Defective Fc gamma RII gene expression in macrophages of NOD mice: genetic linkage with up-regulation of IgG1 and IgG2b in serum.	FCGR2A FCGR2B	2.58e-05	2	177	2	8906852
Pubmed	A new mouse cell-surface antigen (Ly-m20) controlled by a gene linked to Mls locus and defined by monoclonal antibodies.	FCGR2A FCGR2B	2.58e-05	2	177	2	6173319
Pubmed	CD16/32-specific biotinylated 2.4G2 single-chain Fv complexed with avidin-FITC enhances FITC-specific humoral immune response in vivo in a CD16-dependent manner.	FCGR2A FCGR2B	2.58e-05	2	177	2	19951957
Pubmed	FcγRIIB mediates the inhibitory effect of aggregated α-synuclein on microglial phagocytosis.	FCGR2A FCGR2B	2.58e-05	2	177	2	26342897
Pubmed	FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis.	FCGR2A FCGR2B	2.58e-05	2	177	2	14981111
Pubmed	A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice.	FCGR2A FCGR2B	2.58e-05	2	177	2	22290146
Pubmed	Neutrophil responsiveness to IgG, as determined by fixed ratios of mRNA levels for activating and inhibitory FcgammaRII (CD32), is stable over time and unaffected by cytokines.	FCGR2A FCGR2B	2.58e-05	2	177	2	16551965
Pubmed	Analysis of a wild mouse promoter variant reveals a novel role for FcγRIIb in the control of the germinal center and autoimmunity.	FCGR2A FCGR2B	2.58e-05	2	177	2	23109709
Pubmed	Augmentation of pulmonary host defense against Pseudomonas by FcgammaRIIA cDNA transfer to the respiratory epithelium.	FCGR2A FCGR2B	2.58e-05	2	177	2	10449433
Pubmed	Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis.	FCGR2A FCGR2B	2.58e-05	2	177	2	10981970
Pubmed	Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo.	FCGR2A FCGR2B	2.58e-05	2	177	2	24505033
Pubmed	Methods to analyze SNARE-dependent vesicular fusion events that regulate autophagosome biogenesis.	ATG16L1 ATG9A	2.58e-05	2	177	2	25461811
Pubmed	The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN.	FCGR2A FCGR2B	2.58e-05	2	177	2	23411782
Pubmed	The impact of genetic susceptibility to systemic lupus erythematosus on placental malaria in mice.	FCGR2A FCGR2B	2.58e-05	2	177	2	23675429
Pubmed	Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes.	FCGR2A FCGR2B	2.58e-05	2	177	2	2529342
Pubmed	Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG.	FCGR2A FCGR2B	2.58e-05	2	177	2	10330436
Pubmed	Elk1 enhances inflammatory cell infiltration and exacerbates acute lung injury/acute respiratory distress syndrome by suppressing Fcgr2b transcription.	FCGR2A FCGR2B	2.58e-05	2	177	2	38649840
Pubmed	Polymorphism of Fc receptor on murine B cells is Igh-linked.	FCGR2A FCGR2B	2.58e-05	2	177	2	3159826
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	PAPPA2 CSMD2 CSMD3 SVEP1 NCAN CSMD1	2.29e-06	57	122	6	1179
GeneFamily	WD repeat domain containing	ATG16L1 WDR33 EIPR1 EML3 WDR59 FZR1 WDR87 DNAI2 BUB3 WDR77	1.14e-05	262	122	10	362
GeneFamily	Adhesion G protein-coupled receptors, subfamily C\|CELSR cadherins	CELSR3 CELSR2	1.35e-04	3	122	2	913
GeneFamily	Adhesion G protein-coupled receptors, subfamily C\|CELSR cadherins	CELSR3 CELSR2	1.35e-04	3	122	2	1189
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	PKD1L3 NCAN KLRC2 KLRC3	1.65e-04	41	122	4	1298
GeneFamily	Ankyrin repeat domain containing	ANKK1 GIT1 ASB11 ASB9 ASB3 ANKDD1A PLA2G6 ZDHHC13	2.38e-04	242	122	8	403
GeneFamily	Zinc fingers GRF-type\|Topoisomerases	ZCCHC4 APEX2	9.28e-04	7	122	2	135
GeneFamily	Tetratricopeptide repeat domain containing\|Bardet-Biedl syndrome associated\|BBSome	RGPD2 SH3TC2 RGPD1 TMTC4 CTR9	1.09e-03	115	122	5	769
GeneFamily	Immunoglobulin like domain containing	NRCAM HMCN2 FCGR2A FCGR2B IL1R2 CD101	1.99e-03	193	122	6	594
GeneFamily	Mitogen-activated protein kinase-activated protein kinases	RPS6KA1 MAPKAPK3	2.39e-03	11	122	2	1156
GeneFamily	CD molecules\|C-type lectin domain family\|Killer cell lectin like receptors	KLRC2 KLRC3	2.85e-03	12	122	2	621
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	MPL FCGR2C SIGLEC7 FCGR2A FCGR2B IL1R2 CD101 KLRC2	5.28e-03	394	122	8	471
GeneFamily	Dyneins, axonemal	DNAH2 DNAI2	5.75e-03	17	122	2	536
GeneFamily	Armadillo repeat containing\|Importins	KPNA4 KPNA2	6.44e-03	18	122	2	596
ToppCell	facs-Lung-EPCAM-18m-Lymphocytic-Alox5+_Lymphocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PCSK1 PODNL1 ERMP1 CPT1B ZCCHC4 BMP7 ASB3 C12orf42 PSD4	4.61e-08	180	177	9	b28363626f4d2a552abde3434cc1df2e2121aba5
ToppCell	facs-Lung-EPCAM-18m-Lymphocytic-lymphocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PCSK1 PODNL1 ERMP1 CPT1B ZCCHC4 BMP7 ASB3 C12orf42 PSD4	4.61e-08	180	177	9	67b062f2ef7e20f392e00c646f4985c415d40de9
ToppCell	Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic-neutrophil\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ARHGEF28 PKD1L3 CSMD2 HMCN2 FCGR2A IL1R2 ASB11 SULF1 CSMD1	9.16e-08	195	177	9	d3755929ebbbf5e3afde44281e9056ddb614a291
ToppCell	Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ARHGEF28 PKD1L3 CSMD2 HMCN2 FCGR2A IL1R2 ASB11 SULF1 CSMD1	9.16e-08	195	177	9	19853c654ac64b3ae3bc99841c6cb29c8aaba85c
ToppCell	Adult-Immune-enucleated_erythrocyte-D175\|Adult / Lineage, Cell type, age group and donor	ZNF597 COL7A1 KCNH8 NRCAM BMP7 HMCN2 CELSR2 ASB9	1.77e-07	152	177	8	530d5427d8617dcb223d807b73abee0ef89285f3
ToppCell	COVID-19-kidney-Technical/muscle_(Mes)\|kidney / Disease (COVID-19 only), tissue and cell type	CSMD2 CSMD3 TMEM132B TENM2 CNTNAP5 GPR158 NAV3 CSMD1	2.50e-07	159	177	8	5335cbcdeaf2bbd0268bbfe0e45c8c0d288e640d
ToppCell	Basal_cells-IPF_01\|World / lung cells shred on cell class, cell subclass, sample id	PODNL1 COL7A1 NLGN4Y POU3F1 KCTD1 TENM2 BMP7 SYT8	3.48e-07	166	177	8	23c04d1fba0c1733ccd0e4378fae2edde4fd0a7b
ToppCell	facs-Lung-18m-Hematologic-Lymphocytic_NK_ILC-Alox5+_lymphocyte-Alox5+_lymphocyte\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PCSK1 PODNL1 ERMP1 CPT1B BMP7 ASB3 C12orf42 PSD4	5.66e-07	177	177	8	b7cfa3776f58377e35830780650d236b5cceecee
ToppCell	facs-Lung-18m-Hematologic-Lymphocytic_NK_ILC-Alox5+_lymphocyte\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PCSK1 PODNL1 ERMP1 CPT1B BMP7 ASB3 C12orf42 PSD4	5.66e-07	177	177	8	1730e640986e50943bd781b7d949bcc5b7c12dde
ToppCell	COVID-19-Epithelial_cells-Airway_basal\|COVID-19 / group, cell type (main and fine annotations)	COL7A1 KCNH8 BCL11A KCTD1 MAST4 SYT8 EGFR PATJ	8.57e-07	187	177	8	8407a82e98f56a94ea26562bcb6bbe00a8f41661
ToppCell	COPD-Lymphoid-B\|Lymphoid / Disease state, Lineage and Cell class	KCNH8 BCL11A MEF2A MAPK8IP3 TRAK1 PLEKHG1 C12orf42 USP6NL	9.66e-07	190	177	8	1e85ee686ff6dd27c69415d524d54fa825b1daad
ToppCell	Basal_cells-IPF_02\|World / lung cells shred on cell class, cell subclass, sample id	COL7A1 NLGN4Y KCTD1 TENM2 RNF43 BMP7 CELSR2 SYT8	1.01e-06	191	177	8	a98915bad9a4a61dd4cbca798914849b805f4a19
ToppCell	IPF-Stromal-Fibroblast\|World / Disease state, Lineage and Cell class	SH3TC2 FAM180B OLFML3 SVEP1 THBS2 EGFR SULF1 NAV3	1.17e-06	195	177	8	9c32756edb54f0c211185d9a98073fe01fd1526a
ToppCell	Parenchymal-NucSeq-Epithelial-Epi_airway_basal-Basal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	COL7A1 KCNH8 BCL11A KCTD1 TENM2 BMP7 SYT8 SULF1	1.17e-06	195	177	8	6c9c58322c1df891bb4bab56dacb542c8777bb7d
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PCSK1 CAMK1D NRCAM KCTD1 CSMD3 TENM2 NAV3 CSMD1	1.17e-06	195	177	8	2e1df01bf6e4e98e6cd9fb50926e34c5077b8666
ToppCell	IPF-Stromal-Fibroblast\|IPF / Disease state, Lineage and Cell class	SH3TC2 FAM180B OLFML3 SVEP1 THBS2 EGFR SULF1 NAV3	1.22e-06	196	177	8	f7ae604ba32b322d86d68b2b54892e7c6ab06c49
ToppCell	COPD-Stromal-Fibroblast\|World / Disease state, Lineage and Cell class	SH3TC2 FAM180B OLFML3 SVEP1 THBS2 EGFR SULF1 NAV3	1.32e-06	198	177	8	2f13c0b3372af53d1bd85f9546f315c878580a71
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Fibroblasts-Pericyte_2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KCNH8 CHRDL2 KCTD21 TRIP13 SVEP1 SULF1 HAAO	3.35e-06	158	177	7	7f5426585d0d299d2b48e5fcb349950feffdef33
ToppCell	Basal_cells-SSc-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	PCSK1 COL7A1 TENM2 BMP7 METTL24 SYT8 SULF1	4.28e-06	164	177	7	85487a303194f5244956ec1ca2d1758d38117f41
ToppCell	facs-Heart-RV-3m-Lymphocytic-T_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PCSK1 PODNL1 PLCXD2 BMP7 C12orf42 KLRC2 KLRC3	4.64e-06	166	177	7	c0fd3f3f5c3412746da279b856af0d28b9b70c5d
ToppCell	facs-Heart-RV-3m-Lymphocytic\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PCSK1 PODNL1 PLCXD2 BMP7 C12orf42 KLRC2 KLRC3	4.64e-06	166	177	7	33c4876df43b4c1d100699bca47459918bd054d6
ToppCell	facs-Heart-RV-3m-Lymphocytic-T_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PCSK1 PODNL1 PLCXD2 BMP7 C12orf42 KLRC2 KLRC3	4.64e-06	166	177	7	ac9b9df57d65ccbbf9ae3add50c5663efcd30dcb
ToppCell	MS-CD8-proli_CD4\|MS / Condition, Cell_class and T cell subcluster	RGPD2 TMEM132B ADAMTSL5 WDCP ANKDD1A C12orf42 ZNF620	5.86e-06	172	177	7	0b6dd257110b3f17fa71ab18a165b091a9d5ae9a
ToppCell	PND14-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-ILC-ILC_mature\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	PCSK1 PODNL1 ZKSCAN2 BMP7 IL1R2 C12orf42 PSD4	6.81e-06	176	177	7	0f55de48bbc396c187f2a7d1d7da20862c715f9e
ToppCell	IPF-Epithelial-Mesothelial\|IPF / Disease state, Lineage and Cell class	SH3TC2 KLK7 THBS2 MAST4 NLGN4X EGFR SULF1	7.89e-06	180	177	7	1fa54bf4dba72866b2295639d991af639341bc08
ToppCell	PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	COL7A1 IL23A OLFML3 SVEP1 BMP7 HMCN2 NAV3	8.18e-06	181	177	7	3462aa1c08fbaf613b6278ab2c7a5a0940bf537d
ToppCell	PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_mature\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	COL7A1 IL23A OLFML3 SVEP1 BMP7 HMCN2 NAV3	8.18e-06	181	177	7	6730e249cac55ae892cc567d9211615882f3dab4
ToppCell	COPD-Epithelial-Basal\|World / Disease state, Lineage and Cell class	CAMK1G KCTD1 MAST4 SYT8 EGFR SULF1 PATJ	8.18e-06	181	177	7	6d8a886b4afe729f8a05b9c0f4ea9375de735da4
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Oligo-OPC\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KCNH8 C10orf90 BMP7 THBS2 KLF17 KLRC2 KLRC3	8.48e-06	182	177	7	3cc61f5f7ad4a81eba3daf65e122880b5af3adc0
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Oligo-OPC-OPC_L1-6_MYT1\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KCNH8 C10orf90 BMP7 THBS2 KLF17 KLRC2 KLRC3	8.48e-06	182	177	7	5d909e4b5f662905bf1be9c686bbddc3e87d2be9
ToppCell	COPD-Epithelial-Basal\|COPD / Disease state, Lineage and Cell class	COL7A1 CAMK1G KCTD1 MAST4 SYT8 EGFR PATJ	8.79e-06	183	177	7	0f760e393edc91009bf6c7e02eeac039a1dfb4ed
ToppCell	TCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Squamous_Cell_Carcinoma-3\|TCGA-Lung / Sample_Type by Project: Shred V9	COL7A1 NRCAM BCL11A KCTD1 TENM2 BMP7 METTL24	9.10e-06	184	177	7	ea4ccebe2d54279fcc517e4f0bfa652b91a808bb
ToppCell	droplet-Limb_Muscle-nan-3m-Macroglial-unknown\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KLK7 KCNH8 NRCAM POU3F1 POU3F2 CSMD3 CSMD1	9.10e-06	184	177	7	da8d6e7944eb35e6cbea2feb7cbc2894787d723f
ToppCell	TCGA-Cervix-Primary_Tumor-Cervical_Carcinoma-Cervical_Squamous_Cell_Carcinoma-3\|TCGA-Cervix / Sample_Type by Project: Shred V9	UBR4 ERMP1 EML3 MAST4 JMJD7 RIC1	9.43e-06	122	177	6	1ed865f0ecfe304fb86313ff51c04e9052357270
ToppCell	10x3'2.3-week_12-13-Mesenchymal_adipo\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	PODNL1 NRCAM OLFML3 SVEP1 THBS2 EGFR ANGPT4	1.01e-05	187	177	7	f1d0fc625e0e7881b3f290742fd7148d995eb71e
ToppCell	10x3'2.3-week_12-13-Mesenchymal_adipo-stroma\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	PODNL1 NRCAM OLFML3 SVEP1 THBS2 EGFR ANGPT4	1.01e-05	187	177	7	02e7246ef5ad41773d14426254e139b156d45c1d
ToppCell	Control-Lymphoid-B\|Lymphoid / Disease state, Lineage and Cell class	KCNH8 BCL11A MEF2A TRAK1 PLEKHG1 C12orf42 USP6NL	1.01e-05	187	177	7	4e64be635f445276e71f2937f33f041c3a4204ab
ToppCell	10x3'2.3-week_12-13-Mesenchymal_adipo-stroma-adipo-CAR\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	PODNL1 NRCAM OLFML3 SVEP1 THBS2 EGFR ANGPT4	1.01e-05	187	177	7	08c73d125e0638c9e9878165bba2442c266c8a48
ToppCell	IPF-Lymphoid-B\|Lymphoid / Disease state, Lineage and Cell class	KCNH8 BCL11A MEF2A TRAK1 PLEKHG1 C12orf42 USP6NL	1.01e-05	187	177	7	af1327559f7e01bec070881cae52834917c3da65
ToppCell	COVID-19-Heart-Fib_1\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CHRDL2 SVEP1 THBS2 HMCN2 NLGN4X EGFR SULF1	1.05e-05	188	177	7	fe361215f4ba841aa5e1e581fb56f2f4d3ccd201
ToppCell	10x5'-blood-Lymphocytic_B-Naive_B_cells\|blood / Manually curated celltypes from each tissue	KCNH8 CAMK1D BCL11A PLEKHG1 FCGR2B C12orf42 USP6NL	1.05e-05	188	177	7	2b3560b28f9df6f4d4a3e0a4acfa6c7d964ad0fe
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Oligo\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SH3TC2 KCNH8 C10orf90 THBS2 KLRC2 KLRC3 PSD4	1.05e-05	188	177	7	d9692b6048d9b85524a07a1807bdd4757731c151
ToppCell	10x5'-blood-Lymphocytic_B\|blood / Manually curated celltypes from each tissue	KCNH8 CAMK1D BCL11A PLEKHG1 FCGR2B C12orf42 USP6NL	1.08e-05	189	177	7	9837dca502c9a7f42efb0bc74f3e88e7461e7dc8
ToppCell	CTRL-Lymphoid-B_cell\|Lymphoid / Disease state, Lineage and Cell class	CAMK1D DGKD BCL11A MEF2A TRAK1 PLEKHG1 USP6NL	1.08e-05	189	177	7	14f3a8c0f4f057ad4e6839b4c3eeaf956d6dc92e
ToppCell	Fetal_29-31_weeks-Immune-B_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	RGPD2 CAMK1D DGKD BCL11A TRAK1 PLEKHG1 C12orf42	1.12e-05	190	177	7	424550418c1bd4eb070cf3c41cf09fa9d89aef37
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KCNH8 PLCXD2 CSMD2 TENM2 MEF2A CNTNAP5 MAST4	1.12e-05	190	177	7	1bbbf0ce222e51f9fd2daca0c18d3965fd4efd31
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)-Exc_L4_RORB_BHLHE22\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KCNH8 PLCXD2 CSMD2 TENM2 BMP7 CNTNAP5 MAST4	1.20e-05	192	177	7	25460ca9ebd3d49f666394cf99ab77a5e8f77250
ToppCell	PBMC-Severe-Lymphocyte-B-B_cell-B_naive\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	KCNH8 CAMK1D BCL11A PLEKHG1 FCGR2B C12orf42 USP6NL	1.28e-05	194	177	7	82753b90ca3b563275c41b6040ebbcd99b185e24
ToppCell	PBMC-Severe-Lymphocyte-B-B_cell-B_naive-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	KCNH8 CAMK1D BCL11A PLEKHG1 FCGR2B C12orf42 USP6NL	1.33e-05	195	177	7	8f5a664dd65c38afe23c6acd0a9c22ba4fd347ed
ToppCell	PBMC-Severe-Lymphocyte-B-B_cell-B_naive\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	KCNH8 CAMK1D BCL11A PLEKHG1 FCGR2B C12orf42 USP6NL	1.33e-05	195	177	7	e830f0c545be87a1056a4505bdf6845e5ac7750d
ToppCell	COVID-19_Severe-Lymphoid_B-B_naive\|COVID-19_Severe / Disease group, lineage and cell class	KCNH8 CAMK1D BCL11A PLEKHG1 FCGR2B C12orf42 USP6NL	1.33e-05	195	177	7	71563e838fcda34a9a209c5433e0d84420373402
ToppCell	Control-Stromal-Fibroblast\|Control / Disease state, Lineage and Cell class	SH3TC2 OLFML3 SVEP1 THBS2 EGFR SULF1 NAV3	1.37e-05	196	177	7	7ca94477498a84cafcdd9933ee92a6cbde76c70e
ToppCell	Control-Stromal-Fibroblast\|World / Disease state, Lineage and Cell class	SH3TC2 OLFML3 SVEP1 THBS2 EGFR SULF1 NAV3	1.37e-05	196	177	7	1ec7a4daa51b3156db97e1fd6cb925ad311bb4b5
ToppCell	Basal_cells\|World / lung cells shred on cell class, cell subclass, sample id	COL7A1 KCTD1 TENM2 BMP7 CELSR2 SYT8 EGFR	1.42e-05	197	177	7	24360b660000bdfb999d58fbf4e29585a97e1785
ToppCell	Bronchial-NucSeq-Immune_Lymphocytic-B-B_cell\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	KCNH8 CAMK1D NRCAM BCL11A PLEKHG1 FCGR2B C12orf42	1.42e-05	197	177	7	da61afba697ec49ca86e062d35a825280da558ac
ToppCell	primary_auditory_cortex_(A1C)-Neuronal\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NRCAM CSMD3 TMEM132B TENM2 CNTNAP5 GPR158 CSMD1	1.46e-05	198	177	7	6d18b45eda4014759e6dd282d78ffd28df8a6044
ToppCell	Control-Stromal\|Control / Disease state, Lineage and Cell class	SH3TC2 OLFML3 SVEP1 THBS2 EGFR SULF1 NAV3	1.46e-05	198	177	7	ae726b6b7f0a4107899be4d32ac256ffa0bd8d59
ToppCell	3'-Broncho-tracheal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting-Basal_resting_L.0.0.0.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL7A1 PLCXD2 POU3F1 TENM2 BMP7 EGFR IL1R2	1.46e-05	198	177	7	fc00cb25cdc6c31b7f9d397bc9f9a8f4e9708003
ToppCell	COPD-Stromal-Fibroblast\|COPD / Disease state, Lineage and Cell class	FAM180B OLFML3 SVEP1 THBS2 EGFR SULF1 NAV3	1.46e-05	198	177	7	7904af61473cb20064f7a3a1e1bfe8d5913cf317
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Colon_Adenocarcinoma\|TCGA-Colorectal / Sample_Type by Project: Shred V9	EIPR1 TRIP13 RNF43 WDR59 BUB3 WDR77 KPNA2	1.51e-05	199	177	7	cdcdef1d95a8e476de016b1e11ee010438834be0
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARHGEF28 RNF43 EGFR ASB11 C5 PATJ	1.54e-05	133	177	6	5bf5e654653e2c340891f51e3f2a30441b7b6b2b
ToppCell	Biopsy_Other_PF-Mesenchymal-Fibroblasts\|Biopsy_Other_PF / Sample group, Lineage and Cell type	PAPPA2 FAM180B OLFML3 SVEP1 THBS2 HMCN2 SULF1	1.56e-05	200	177	7	9996b6887cf2b1936e10a1aa396f09fd8da5f4c4
ToppCell	COVID-19-COVID-19_Severe-Lymphocyte-B-B_naive\|COVID-19_Severe / Disease, condition lineage and cell class	KCNH8 CAMK1D BCL11A PLEKHG1 FCGR2B C12orf42 USP6NL	1.56e-05	200	177	7	5ba9c541fa356d34f392a63274dcd7bfb844cbb6
ToppCell	Macroglial-Polydendrocytes-PDGFRA-\|Macroglial / cells hierarchy compared to all cells using T-Statistic	CSMD2 CSMD3 CNTNAP5 NLGN4X GPR158 TENM1 CSMD1	1.56e-05	200	177	7	f17b5a54e8f9eba9dcd0808ba4e8d275ac41bce2
ToppCell	Macroglial-Polydendrocytes-PDGFRA--\|Macroglial / cells hierarchy compared to all cells using T-Statistic	CSMD2 CSMD3 CNTNAP5 NLGN4X GPR158 TENM1 CSMD1	1.56e-05	200	177	7	cc3409518f8b436ea92deb955e81114b3f410ff7
ToppCell	Macroglial-Polydendrocytes-PDGFRA\|Macroglial / cells hierarchy compared to all cells using T-Statistic	CSMD2 CSMD3 CNTNAP5 NLGN4X GPR158 TENM1 CSMD1	1.56e-05	200	177	7	c24a3099e3d96d8b72f6d05286bb355d661a0377
ToppCell	Macroglial-Polydendrocytes-PDGFRA---\|Macroglial / cells hierarchy compared to all cells using T-Statistic	CSMD2 CSMD3 CNTNAP5 NLGN4X GPR158 TENM1 CSMD1	1.56e-05	200	177	7	4fc3de4bff7ed2bf40b38462c4b4e9b87af6a4ca
ToppCell	Macroglial-Polydendrocytes-PDGFRA----L1-6\|Macroglial / cells hierarchy compared to all cells using T-Statistic	CSMD2 CSMD3 CNTNAP5 NLGN4X GPR158 TENM1 CSMD1	1.56e-05	200	177	7	310cd53db1c137f6af74e6ae682221d7ac27310c
ToppCell	Macroglial-Polydendrocytes\|Macroglial / cells hierarchy compared to all cells using T-Statistic	CSMD2 CSMD3 CNTNAP5 NLGN4X GPR158 TENM1 CSMD1	1.56e-05	200	177	7	961858738ce35db8760c8c2e136f8369bc444ccf
ToppCell	Substantia_nigra-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cspg5_(Cspg5)\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	KCNH8 RTTN PKD1L3 RNF43 AARSD1	2.99e-05	90	177	5	3817a5b0235e632d976ea565175bdbebbd959bf0
ToppCell	Substantia_nigra-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cspg5_(Cspg5)-\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	KCNH8 RTTN PKD1L3 RNF43 AARSD1	2.99e-05	90	177	5	a528f5dcee1a356dea89ff2588d2e0f276f2d5fc
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	KCTD1 IRF9 THBS2 SULF1 DNAI2 NAV3	3.05e-05	150	177	6	909ccab92855f5f049dc29593aadab1ea973297b
ToppCell	Entopeduncular-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Rgs5Acta2.Ccnd1_(Mural.Rgs5Acta2.Ccnd1)\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	PAPPA2 CLEC6A METTL24 HMCN2 ASB11	3.68e-05	94	177	5	d78535a7a0fda7299b01912333b944dc5e0a0361
ToppCell	Entopeduncular-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Rgs5Acta2.Ccnd1_(Mural.Rgs5Acta2.Ccnd1)-\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	PAPPA2 CLEC6A METTL24 HMCN2 ASB11	3.68e-05	94	177	5	dfc3f7977b9df433009d1d2d465b64a2de5806e2
ToppCell	356C-Fibroblasts-Fibroblast-D-\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	SH3TC2 CLEC6A RPS6KA1 LRRC4 IL23A FCGR2B	4.22e-05	159	177	6	299e2162a82e31196d7f3a110c2db622349edfff
ToppCell	356C-Fibroblasts-Fibroblast-D\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	SH3TC2 CLEC6A RPS6KA1 LRRC4 IL23A FCGR2B	4.22e-05	159	177	6	0a3a363b30a8c741e1a3e2525725108d03c21776
ToppCell	facs-Skin-Anagen-24m-Epithelial-inner_bulge\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SH3TC2 PLEKHG1 FZR1 CELSR2 PLA2G6	4.96e-05	100	177	5	97ca9cda55a05fbb4d1f5d61f847c965e014f05c
ToppCell	PND14-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	PCSK1 PODNL1 BMP7 IL1R2 C12orf42 KLRC2	5.19e-05	165	177	6	004d793bf5bb6fb3b7bf38baf11b32d46375fe4d
ToppCell	ICU-NoSEP-Lymphocyte-T_NK-MAIT\|ICU-NoSEP / Disease, Lineage and Cell Type	POLA1 ZKSCAN2 TRIP13 ZNF620 PLA2G6 RAVER1	5.37e-05	166	177	6	d3fa2e42497201f1ca57f4f977fbaa0def950033
ToppCell	Basal_cells-IPF_03\|World / lung cells shred on cell class, cell subclass, sample id	COL7A1 NLGN4Y BMP7 THBS2 CELSR2 SYT8	5.74e-05	168	177	6	48089fa2d4a0f31a72405717119b767a92571f01
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Monocytic\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	BCL11A TRIP13 FCGR2A FCGR2B IL1R2 C12orf42	5.93e-05	169	177	6	b2fdf9f842dc7c181bc951a8a6932c916ed835ef
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Monocytic-Monocyte-derived_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	BCL11A TRIP13 FCGR2A FCGR2B IL1R2 C12orf42	5.93e-05	169	177	6	2322f03a115c662f808ebfc892192b7d38d48181
ToppCell	PND14-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-ILC\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	PCSK1 PODNL1 ZKSCAN2 BMP7 IL1R2 C12orf42	5.93e-05	169	177	6	e36b8cd0230bbb761df7606129ebfd77111af10b
ToppCell	URO-Lymphocyte-B-B_intermediate\|URO / Disease, Lineage and Cell Type	NLGN4Y BCL11A PLEKHG1 FCGR2B C12orf42 USP6NL	6.13e-05	170	177	6	e11d1510518cedabeece96d4adbb90999e6326fa
ToppCell	droplet-Kidney-nan-21m-Myeloid-nan\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TBKBP1 CAMK1D KCP OLFML3 FCGR2B MAPKAPK3	6.13e-05	170	177	6	510625bd725d3590cffcd7acd1d42219f6eb1139
ToppCell	5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting-Basal_resting_L.0.0.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL7A1 NRCAM POU3F1 BMP7 EGFR CSMD1	6.13e-05	170	177	6	0cc20322cb3e3e7bbd4daad8785c99f80e355c16
ToppCell	5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL7A1 NRCAM POU3F1 BMP7 EGFR CSMD1	6.13e-05	170	177	6	2d880223d01bde4bf777bd6f50b7d2768489075f
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	POMT1 LRRC4 MAPK8IP3 NHSL1 CNTNAP5 MAP3K19	6.33e-05	171	177	6	1854a777d9eb9d3fc3ed3632332a6f89ce8131da
ToppCell	facs-Lung-3m-Hematologic-lymphocytic-CD4-positive,_alpha-beta_T_cell-CD4-positive,_alpha-beta_T_cell_l21\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PLCXD2 BRME1 PKD1L3 USP16 TTLL12 WDR77	6.33e-05	171	177	6	f1fdc0ec3399ed6955976d02be7e5fc329a64276
ToppCell	5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Suprabasal-\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NRCAM PKD1L3 TENM2 CELSR2 HAAO CSMD1	6.33e-05	171	177	6	121e63ca281ad765d76c2afb3b4d441329b47f81
ToppCell	cellseq2-Epithelial-Epithelial_Airway-Basal/Suprabasal-Basal\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	GARIN5B COL7A1 POU3F1 KCTD1 BMP7 EGFR	6.54e-05	172	177	6	e9095c3dac66cf93d31f5f88364b565abacb1e2d
ToppCell	Lymphoid-Lymphoid-B_cells_(cycle)\|Lymphoid / shred on cell class and cell subclass (v4)	POLA1 NUDT2 TRIP13 CELSR3 HSPA9 KPNA2	6.54e-05	172	177	6	f39822afcc35f0fbf68b8ffd1894e4b6c8d7a80c
ToppCell	BAL-Mild-Epithelial-Epithelial-AT1/AT2\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NRCAM CSMD2 NLGN4X EGFR CYP26C1 NAV3	6.97e-05	174	177	6	b7f5492ce8098f7eb0aef30ee558d00738d59d0e
ToppCell	BAL-Mild-Epithelial-Epithelial-AT1/AT2-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	NRCAM CSMD2 NLGN4X EGFR CYP26C1 NAV3	6.97e-05	174	177	6	71730503be3d9c839c4c9e950145e2101d682a1c
ToppCell	facs-Pancreas-Exocrine-3m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRYL ADAR USP16 MAST4 GPR158 DOP1A	6.97e-05	174	177	6	f1fe1f4216748a9562dd03bd48c70b23c7ff4d1d
ToppCell	BAL-Mild-Epithelial-Epithelial-AT1/AT2\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	NRCAM CSMD2 NLGN4X EGFR CYP26C1 NAV3	6.97e-05	174	177	6	ee8ac51fa0b426ad7b7453371bb79c8bf8c1d358
ToppCell	BAL-Mild-Epithelial-Epithelial-AT1/AT2-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NRCAM CSMD2 NLGN4X EGFR CYP26C1 NAV3	6.97e-05	174	177	6	cafe4d6b5f08d8888e9db6e196c66df991c03e7b
ToppCell	COVID_non-vent-Lymphocytic-T_cell-Gamma_Delta_T_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	CACNA1S CHRDL2 UGT3A1 DPPA2 MAP3K19	7.15e-05	108	177	5	04bfb90634b691020f246a8afbebd3bf944d1e0e
ToppCell	Nasal_Brush-Epithelial-Basal_2\|Nasal_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X	COL7A1 NRCAM POU3F1 CSMD3 IL1R2 TENM1	7.42e-05	176	177	6	fc5787946f5a10056d326d070620575ae4081836
ToppCell	Nasal_Brush-Epithelial-Basal_2\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	COL7A1 NRCAM POU3F1 CSMD3 IL1R2 TENM1	7.42e-05	176	177	6	5daaba0853afe7d20d4635169ccd4f96e735b938
Drug	Norfloxacin [70458-96-7]; Down 200; 12.6uM; HL60; HG-U133A	PAPPA2 GADD45B ERMP1 POMT1 INO80D EML3 MAPK8IP3 TRAK1 TAOK2 LIG3 PSME4 ATG9A	4.04e-08	197	174	12	1406_DN
Drug	Intravenous Immunoglobulin	FCGR2C FCGR2A FCGR2B C5	2.25e-07	8	174	4	DB00028
Drug	Oxethazaine [126-27-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A	PAPPA2 PODNL1 COL7A1 BCL11A CPT1B ZCCHC4 FZR1 SIGLEC7 NCAN PLA2G6 PSD4	3.81e-07	198	174	11	1484_UP
Drug	Cetuximab	FCGR2C FCGR2A EGFR FCGR2B	1.56e-06	12	174	4	DB00002
Drug	Trastuzumab	FCGR2C FCGR2A EGFR FCGR2B	2.23e-06	13	174	4	DB00072
Drug	Orlistat; Up 200; 10uM; PC3; HT_HG-U133A	PAPPA2 GIT1 BCL11A SLC22A7 CEP164 FZR1 SIGLEC7 EGFR SULF1 PSD4	2.82e-06	196	174	10	6420_UP
Drug	Benzathine benzylpenicillin [5928-84-7]; Up 200; 4.2uM; PC3; HT_HG-U133A	DNAH2 BCL11A EML3 SLC22A7 ZCCHC4 FZR1 LMAN1 SULF1 DOP1A PSD4	2.82e-06	196	174	10	4022_UP
Drug	Quipazine dimaleate salt [4774-24-7]; Up 200; 9uM; MCF7; HT_HG-U133A	PODNL1 COL7A1 ARHGEF17 SVEP1 MAPK8IP3 TRAK1 ZCCHC4 BMP7 SIGLEC7 EGFR	2.95e-06	197	174	10	2782_UP
Drug	15(S)-15-methyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A	SH3TC2 WDR33 RNF43 WDR59 FZR1 CELSR3 EGFR TENM1 BRINP2 PLA2G6	3.23e-06	199	174	10	7494_DN
Drug	Ascorbic acid [50-81-7]; Down 200; 22.4uM; MCF7; HT_HG-U133A	KPNA4 PAPPA2 CPT1B INO80D BMP7 FZR1 LMAN1 BRINP2 PATJ PSD4	3.23e-06	199	174	10	5407_DN
Drug	MDL 20,610	FCGR2C FCGR2A FCGR2B	4.34e-06	5	174	3	CID000128209
Drug	TAN-1030A	FCGR2C FCGR2A FCGR2B	8.63e-06	6	174	3	CID009576886
Drug	AC1MHTIN	FCGR2C FCGR2A FCGR2B	1.50e-05	7	174	3	CID003011133
Drug	TAN-999	FCGR2C FCGR2A FCGR2B	1.50e-05	7	174	3	CID000130283
Drug	Iopanoic acid [96-83-3]; Up 200; 7uM; HL60; HT_HG-U133A	PAPPA2 COL7A1 NRCAM MEF2A SVEP1 TAOK2 BMP7 CELSR3 PLA2G6	1.92e-05	194	174	9	2965_UP
Drug	Lynestrenol [52-76-6]; Up 200; 14uM; HL60; HG-U133A	PODNL1 NUDT2 INO80D LIG3 BMP7 SIGLEC7 LMAN1 IL1R2 CD101	2.00e-05	195	174	9	2037_UP
Drug	Minaprine dihydrochloride [25953-17-7]; Up 200; 10.8uM; HL60; HG-U133A	GADD45B NUDT2 POMT1 MAPK8IP3 DHRS12 TXNL4A LMAN1 IL1R2 PSD4	2.08e-05	196	174	9	1968_UP
Drug	Lovastatin [75330-75-5]; Up 200; 9.8uM; PC3; HT_HG-U133A	PAPPA2 CAMK1G RNF43 LIG3 BMP7 BRINP2 PLA2G6 USP6NL PSD4	2.08e-05	196	174	9	6633_UP
Drug	CP-320650-01 [172079-28-6]; Down 200; 1uM; PC3; HT_HG-U133A	COL7A1 ZKSCAN8 CPT1B CEP164 BMP7 CELSR2 CD101 PLA2G6 PSD4	2.16e-05	197	174	9	3825_DN
Drug	Flutamide [13311-84-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A	COL7A1 GIT1 WDR33 ARHGEF17 WDR59 CEP164 MAPK8IP3 FZR1 PATJ	2.16e-05	197	174	9	3885_DN
Drug	CP-319743 [172078-87-4]; Down 200; 10uM; MCF7; HT_HG-U133A	PAPPA2 PODNL1 COL7A1 CPT1B INO80D TRAK1 LIG3 EGFR ASB9	2.16e-05	197	174	9	7486_DN
Drug	Diloxanide furoate [3736-81-0]; Down 200; 12.2uM; MCF7; HT_HG-U133A	TBKBP1 CAMK1D CPT1B IL23A INO80D RNF43 TRAK1 FZR1 HAAO	2.16e-05	197	174	9	3399_DN
Drug	Meclocycline sulfosalicylate [73816-42-9]; Down 200; 5.8uM; MCF7; HT_HG-U133A	GIT1 MAPK8IP3 TRAK1 DHRS12 TXNL4A MAST4 EGFR SULF1 PSD4	2.16e-05	197	174	9	3277_DN
Drug	Lovastatin [75330-75-5]; Down 200; 9.8uM; MCF7; HT_HG-U133A	ATG16L1 GIT1 ARHGEF17 CEP164 ZCCHC4 BMP7 FZR1 ASB9 PSD4	2.16e-05	197	174	9	2854_DN
Drug	Chlortetracycline hydrochloride [64-72-2]; Up 200; 7.8uM; MCF7; HT_HG-U133A	CEP164 SVEP1 TAOK2 FZR1 DHRS12 TXNL4A LMAN1 ANGPT4 PSD4	2.25e-05	198	174	9	1541_UP
Drug	Betazole hydrochloride; Down 200; 27uM; MCF7; HT_HG-U133A	PODNL1 ATG16L1 ARHGEF17 EML3 WDR59 MAPK8IP3 FZR1 BRINP2 PSD4	2.25e-05	198	174	9	5445_DN
Drug	Indoprofen [31842-01-0]; Down 200; 14.2uM; MCF7; HT_HG-U133A	CAMK1D GIT1 DGKD INO80D MAPK8IP3 TRAK1 IRF9 FZR1 SLC12A9	2.34e-05	199	174	9	3345_DN
Drug	Clonidine hydrochloride [4205-91-8]; Down 200; 15uM; MCF7; HT_HG-U133A	CAMK1D GIT1 EML3 MAPK8IP3 TRAK1 TAOK2 BMP7 SLC12A9 PATJ	2.34e-05	199	174	9	6814_DN
Drug	AC1NSK5W	FCGR2C FCGR2A FCGR2B	3.56e-05	9	174	3	CID005311182
Drug	3,5-dichlorophenol	PRKRA C5 HSPA9	3.56e-05	9	174	3	CID000011571
Drug	Palivizumab	FCGR2C FCGR2A FCGR2B	5.06e-05	10	174	3	DB00110
Drug	Denny-Jaffe reagent	FCGR2C FCGR2A FCGR2B	5.06e-05	10	174	3	CID003035979
Drug	Bevacizumab	FCGR2C FCGR2A FCGR2B	6.92e-05	11	174	3	DB00112
Drug	Tositumomab	FCGR2C FCGR2A FCGR2B	6.92e-05	11	174	3	DB00081
Drug	Alemtuzumab	FCGR2C FCGR2A FCGR2B	6.92e-05	11	174	3	DB00087
Drug	Efalizumab	FCGR2C FCGR2A FCGR2B	6.92e-05	11	174	3	DB00095
Drug	Alefacept	FCGR2C FCGR2A FCGR2B	6.92e-05	11	174	3	DB00092
Drug	Daclizumab	FCGR2C FCGR2A FCGR2B	9.17e-05	12	174	3	DB00111
Drug	Natalizumab	FCGR2C FCGR2A FCGR2B	9.17e-05	12	174	3	DB00108
Drug	Rituximab	FCGR2C FCGR2A FCGR2B	9.17e-05	12	174	3	DB00073
Drug	Ibritumomab	FCGR2C FCGR2A FCGR2B	9.17e-05	12	174	3	DB00078
Drug	Adalimumab	FCGR2C FCGR2A FCGR2B	9.17e-05	12	174	3	DB00051
Drug	Gemtuzumab ozogamicin	FCGR2C FCGR2A FCGR2B	9.17e-05	12	174	3	DB00056
Drug	Dehydroisoandosterone 3-acetate [853-23-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A	GADD45B PODNL1 WDR33 ARHGEF17 SVEP1 IRF9 FZR1 MAST4	1.03e-04	188	174	8	5019_UP
Drug	Hexestrol [84-16-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A	PAPPA2 GADD45B PODNL1 KLK7 SIGLEC7 DNAI2 TENM1 PLA2G6	1.15e-04	191	174	8	6077_UP
Drug	Meclozine dihydrochloride [1104-22-9]; Down 200; 8.6uM; MCF7; HT_HG-U133A	PODNL1 ATG16L1 GIT1 ARHGEF17 INO80D TAOK2 FZR1 SULF1	1.15e-04	191	174	8	5607_DN
Drug	Basiliximab	FCGR2C FCGR2A FCGR2B	1.19e-04	13	174	3	DB00074
Drug	Methionine sulfoximine (L) [15985-39-4]; Up 200; 22.2uM; MCF7; HT_HG-U133A	POU3F2 BCL11A ARHGEF17 IL23A MAPK8IP3 TAOK2 TENM1 BRINP2	1.19e-04	192	174	8	4151_UP
Drug	17-AAG; Down 200; 1uM; PC3; HT_HG-U133A	COL7A1 BCL11A CPT1B EML3 TRAK1 FZR1 LMAN1 BRINP2	1.23e-04	193	174	8	5919_DN
Drug	Dubinidine [22964-77-8]; Up 200; 14.6uM; PC3; HT_HG-U133A	MPL PODNL1 NRCAM RNF43 TAOK2 CELSR3 IL1R2 PATJ	1.28e-04	194	174	8	5774_UP
Drug	Sulmazole [73384-60-8]; Down 200; 14uM; HL60; HT_HG-U133A	PAPPA2 PODNL1 WDR33 INO80D BMP7 SIGLEC7 CELSR2 IL1R2	1.32e-04	195	174	8	2153_DN
Drug	Talampicillin hydrochloride [39878-70-1]; Up 200; 7.8uM; PC3; HT_HG-U133A	GADD45B ATG16L1 KLK7 BCL11A CELSR3 EGFR IL1R2 NAV3	1.32e-04	195	174	8	7254_UP
Drug	S(+)-Terguride [37686-84-3]; Up 200; 11.8uM; PC3; HT_HG-U133A	COL7A1 WDR33 BCL11A CPT1B EML3 CELSR2 IL1R2 PLA2G6	1.32e-04	195	174	8	6299_UP
Drug	Scopoletin [92-61-5]; Down 200; 20.8uM; MCF7; HT_HG-U133A	POLA1 CPT1B TRAK1 ZCCHC4 BMP7 FZR1 DHRS12 EGFR	1.32e-04	195	174	8	6510_DN
Drug	Apomorphine hydrochloride hemihydrate [41372-20-7]; Up 200; 6.4uM; MCF7; HT_HG-U133A	PODNL1 GIT1 EML3 FZR1 MAST4 EGFR C5 PATJ	1.32e-04	195	174	8	5283_UP
Drug	Alfaxalone [23930-19-0]; Up 200; 12uM; MCF7; HT_HG-U133A	BCL11A LIG3 FZR1 SIGLEC7 EGFR ANGPT4 CD101 PLA2G6	1.32e-04	195	174	8	5451_UP
Drug	3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; PC3; HT_HG-U133A	COL7A1 BCL11A CPT1B MAPK8IP3 TAOK2 LIG3 PSME4 PATJ	1.32e-04	195	174	8	4664_DN
Drug	radicicol, diheterospora chlamydosporia; Down 200; 0.1uM; MCF7; HT_HG-U133A	PAPPA2 GADD45B ARHGEF17 CEP164 TRAK1 LIG3 FZR1 MAST4	1.32e-04	195	174	8	5579_DN
Drug	Ergocryptine-alpha [511-09-1]; Up 200; 7uM; PC3; HT_HG-U133A	TBKBP1 NRCAM POU3F2 MAPK8IP3 DHRS12 MAST4 PLA2G6 C5	1.37e-04	196	174	8	3817_UP
Drug	BAS 012416453; Up 200; 38uM; MCF7; HT_HG-U133A	ATG16L1 MAPK8IP3 TRAK1 DHRS12 MAST4 EGFR PATJ PSD4	1.37e-04	196	174	8	6880_UP
Drug	Sulfadimethoxine [122-11-2]; Down 200; 12.8uM; PC3; HT_HG-U133A	PODNL1 GIT1 SVEP1 MAPK8IP3 ZCCHC4 LIG3 CD101 PSD4	1.37e-04	196	174	8	3702_DN
Drug	Asiaticoside [16830-15-2]; Up 200; 4.2uM; HL60; HT_HG-U133A	NRCAM UBR4 EML3 CEP164 SIGLEC7 PLA2G6 USP6NL PSD4	1.37e-04	196	174	8	2943_UP
Drug	Ethotoin [86-35-1]; Down 200; 19.6uM; MCF7; HT_HG-U133A	PAPPA2 WDR33 CPT1B ARHGEF17 WDR59 FZR1 MAST4 PSD4	1.37e-04	196	174	8	3892_DN
Drug	Muramic acid, N-acetyl [10597-89-4]; Up 200; 13.6uM; PC3; HT_HG-U133A	PODNL1 COL7A1 TBKBP1 SVEP1 MAPK8IP3 FZR1 SULF1 PSD4	1.37e-04	196	174	8	4582_UP
Drug	Lithocholic acid [434-13-9]; Down 200; 10.6uM; PC3; HT_HG-U133A	PAPPA2 PODNL1 INO80D MAPK8IP3 TAOK2 BMP7 DHRS12 PATJ	1.37e-04	196	174	8	3816_DN
Drug	Beclomethasone dipropionate [5534-09-8]; Down 200; 7.6uM; PC3; HT_HG-U133A	TBKBP1 GIT1 IL23A WDR59 MAPK8IP3 CELSR3 CELSR2 BRINP2	1.37e-04	196	174	8	4580_DN
Drug	Hexestrol [84-16-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A	GADD45B ATG16L1 EML3 FZR1 LMAN1 CELSR2 IL1R2 PATJ	1.42e-04	197	174	8	6252_UP
Drug	Rauwolscine hydrochloride [6211-32-1]; Up 200; 10.2uM; MCF7; HT_HG-U133A	ARHGEF28 RNF43 MAPK8IP3 TRAK1 TAOK2 FZR1 DNAI2 ATG9A	1.42e-04	197	174	8	6274_UP
Drug	chlorpromazine hydrochloride; Up 200; 1uM; PC3; HT_HG-U133A	SH3TC2 GIT1 IL23A EML3 CEP164 ZCCHC4 EGFR DNAI2	1.42e-04	197	174	8	1217_UP
Drug	Esculin Hydrate [531-75-9]; Up 200; 11.8uM; PC3; HT_HG-U133A	PAPPA2 INO80D EML3 SVEP1 MAPK8IP3 LMAN1 EGFR PLA2G6	1.42e-04	197	174	8	6310_UP
Drug	Cefaclor [70356-03-5]; Up 200; 10.4uM; PC3; HT_HG-U133A	ARHGEF17 EML3 CEP164 LIG3 FZR1 BRINP2 PLA2G6 PSD4	1.42e-04	197	174	8	6622_UP
Drug	Brinzolamide [138890-62-7]; Down 200; 10.4uM; MCF7; HT_HG-U133A	KPNA4 ATG16L1 DGKD INO80D WDR59 LMAN1 SULF1 PLA2G6	1.42e-04	197	174	8	3230_DN
Drug	Riluzole hydrochloride; Up 200; 14.8uM; PC3; HT_HG-U133A	COL7A1 NRCAM UBR4 POU3F2 SLC22A7 BMP7 FZR1 PATJ	1.42e-04	197	174	8	3666_UP
Drug	Amoxicillin [26787-78-0]; Up 200; 11uM; MCF7; HT_HG-U133A	CPT1B RNF43 SVEP1 TRAK1 DHRS12 MAST4 IL1R2 PSD4	1.42e-04	197	174	8	2620_UP
Drug	Ceftazidime pentahydrate [78439-06-2]; Up 200; 6.2uM; HL60; HG-U133A	NUDT2 CAMK1G POMT1 TAOK2 LIG3 BMP7 SIGLEC7 LMAN1	1.42e-04	197	174	8	1721_UP
Drug	Dinoprost trometamol [38362-01-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A	COL7A1 GIT1 DGKD RNF43 IRF9 MAST4 SULF1 PATJ	1.42e-04	197	174	8	3308_DN
Drug	Tolmetin sodium salt dihydrate [64490-92-2]; Up 200; 12.6uM; PC3; HT_HG-U133A	PAPPA2 RNF43 SLC22A7 FZR1 SULF1 ANGPT4 CD101 PLA2G6	1.42e-04	197	174	8	4088_UP
Drug	Zoxazolamine [61-80-3]; Up 200; 23.8uM; PC3; HT_HG-U133A	PODNL1 GIT1 EML3 CEP164 MAPK8IP3 FZR1 CELSR2 NCAN	1.47e-04	198	174	8	6290_UP
Drug	Quinic acid [86-68-0]; Up 200; 19.6uM; PC3; HT_HG-U133A	COL7A1 WDR33 POMT1 MAPK8IP3 TRAK1 FZR1 PLA2G6 PATJ	1.47e-04	198	174	8	7317_UP
Drug	Ketoprofen [22071-15-4]; Down 200; 15.8uM; MCF7; HT_HG-U133A	PAPPA2 TBKBP1 TAOK2 LIG3 DHRS12 PHF20L1 SLC12A9 PLA2G6	1.47e-04	198	174	8	2316_DN
Drug	Nifenazone [2139-47-1]; Down 200; 13uM; MCF7; HT_HG-U133A	ATG16L1 GIT1 EML3 TRAK1 IRF9 LMAN1 PATJ PSD4	1.47e-04	198	174	8	6016_DN
Drug	Dimenhydrinate [523-87-5]; Up 200; 8.6uM; HL60; HT_HG-U133A	PAPPA2 TBKBP1 UBR4 CEP164 MAPK8IP3 FZR1 CELSR2 SULF1	1.47e-04	198	174	8	2400_UP
Drug	Piperidolate hydrochloride [129-77-1]; Up 200; 11.2uM; HL60; HT_HG-U133A	PAPPA2 NRCAM SLC22A7 TAOK2 BMP7 NLGN4X DNAI2 DOP1A	1.47e-04	198	174	8	6129_UP
Drug	0175029-0000 [211245-78-2]; Up 200; 10uM; PC3; HT_HG-U133A	KLK7 WDR59 BMP7 FZR1 DHRS12 SIGLEC7 EGFR PLA2G6	1.47e-04	198	174	8	3691_UP
Drug	Methoxamine hydrochloride [61-16-5]; Up 200; 16.2uM; MCF7; HT_HG-U133A	TBKBP1 POU3F2 CPT1B RNF43 EML3 TRAK1 BMP7 FZR1	1.47e-04	198	174	8	2848_UP
Drug	Abciximab	FCGR2C FCGR2A FCGR2B	1.50e-04	14	174	3	DB00054
Drug	Etanercept	FCGR2C FCGR2A FCGR2B	1.50e-04	14	174	3	DB00005
Drug	Ethaverine hydrochloride [985-13-7]; Up 200; 9.2uM; MCF7; HT_HG-U133A	NUDT2 INO80D RNF43 EML3 CEP164 MAST4 DNAI2 C5	1.52e-04	199	174	8	5337_UP
Drug	Cinnarizine [298-57-7]; Up 200; 10.8uM; PC3; HT_HG-U133A	GIT1 MAPK8IP3 FZR1 NLGN4X CELSR3 SULF1 PLA2G6 C5	1.52e-04	199	174	8	5817_UP
Drug	Isopyrin hydrochloride [18342-39-7]; Down 200; 14.2uM; MCF7; HT_HG-U133A	CPT1B MEF2A CEP164 MAPK8IP3 TRAK1 FZR1 PLA2G6 PSD4	1.52e-04	199	174	8	6097_DN
Drug	Methionine sulfoximine (L) [15985-39-4]; Up 200; 22.2uM; HL60; HT_HG-U133A	PODNL1 SLC22A7 TAOK2 LIG3 BMP7 DHRS12 PLA2G6 DOP1A	1.52e-04	199	174	8	2470_UP
Drug	Rifampicin [13292-46-1]; Up 200; 4.8uM; PC3; HT_HG-U133A	PAPPA2 DNAH2 INO80D EML3 BMP7 FZR1 SULF1 PLA2G6	1.52e-04	199	174	8	4008_UP
Drug	Molsidomine [25717-80-0]; Down 200; 16.6uM; MCF7; HT_HG-U133A	PODNL1 ARHGEF17 WDR59 MAPK8IP3 TAOK2 MAST4 WDCP PATJ	1.52e-04	199	174	8	5426_DN
Drug	Fenbendazole [43210-67-9]; Up 200; 13.4uM; PC3; HT_HG-U133A	COL7A1 TBKBP1 CAMK1D NRCAM POU3F1 MAPK8IP3 MAST4 CELSR3	1.52e-04	199	174	8	3805_UP
Drug	Sulfinpyrazone [57-96-5]; Down 200; 9.8uM; PC3; HT_HG-U133A	ATG16L1 COL7A1 GIT1 BCL11A CPT1B MEF2A MAPK8IP3 FZR1	1.52e-04	199	174	8	5753_DN
Drug	radicicol; Down 200; 0.1uM; PC3; HG-U133A	PODNL1 BRME1 BCL11A EML3 TRAK1 TAOK2 EGFR HAAO	1.52e-04	199	174	8	484_DN
Drug	Tubocurarine chloride pentahydrate (+) [6989-98-6]; Down 200; 5.2uM; HL60; HG-U133A	TTI2 BCL11A INO80D EML3 TRAK1 PHF20L1 WDR77 PSD4	1.52e-04	199	174	8	1738_DN
Drug	Bretylium tosylate [61-75-6]; Down 200; 9.6uM; PC3; HT_HG-U133A	ARHGEF28 INO80D MEF2A FZR1 MAST4 LMAN1 TENM1 BRINP2	1.52e-04	199	174	8	6674_DN
Drug	Bephenium hydroxynaphthoate [3818-50-6]; Up 200; 9uM; HL60; HT_HG-U133A	PAPPA2 KLK7 GIT1 WDR59 SIGLEC7 CELSR2 IL1R2 ASB9	1.52e-04	199	174	8	3089_UP
Drug	Suxibuzone [27470-51-5]; Down 200; 9.2uM; HL60; HT_HG-U133A	GADD45B FRYL INO80D EML3 CEP164 FZR1 SLC12A9 C5	1.52e-04	199	174	8	2503_DN
Disease	malaria (implicated_via_orthology)	FCGR2C FCGR2A FCGR2B	1.57e-05	9	171	3	DOID:12365 (implicated_via_orthology)
Disease	alcohol and nicotine codependence	RGPD2 RGPD1 PLEKHG1	5.24e-05	13	171	3	EFO_0004776
Disease	Drug habituation	NRCAM EIPR1 CSMD3 TENM2 CSMD1 PATJ	5.79e-05	115	171	6	C0013170
Disease	Drug abuse	NRCAM EIPR1 CSMD3 TENM2 CSMD1 PATJ	5.79e-05	115	171	6	C0013146
Disease	Prescription Drug Abuse	NRCAM EIPR1 CSMD3 TENM2 CSMD1 PATJ	5.79e-05	115	171	6	C4316881
Disease	Substance-Related Disorders	NRCAM EIPR1 CSMD3 TENM2 CSMD1 PATJ	5.79e-05	115	171	6	C0236969
Disease	Drug Use Disorders	NRCAM EIPR1 CSMD3 TENM2 CSMD1 PATJ	5.79e-05	115	171	6	C0013222
Disease	Drug Dependence	NRCAM EIPR1 CSMD3 TENM2 CSMD1 PATJ	5.79e-05	115	171	6	C1510472
Disease	Substance Dependence	NRCAM EIPR1 CSMD3 TENM2 CSMD1 PATJ	5.79e-05	115	171	6	C0038580
Disease	Substance Use Disorders	NRCAM EIPR1 CSMD3 TENM2 CSMD1 PATJ	5.79e-05	115	171	6	C0038586
Disease	Organic Mental Disorders, Substance-Induced	NRCAM EIPR1 CSMD3 TENM2 CSMD1 PATJ	5.79e-05	115	171	6	C0029231
Disease	Substance abuse problem	NRCAM EIPR1 CSMD3 TENM2 CSMD1 PATJ	6.08e-05	116	171	6	C0740858
Disease	low affinity immunoglobulin gamma Fc region receptor II-a measurement	FCGR2C FCGR2A FCGR2B	1.22e-04	17	171	3	EFO_0021969
Disease	retinal drusen	GADD45B SVEP1 PLEKHG1 C12orf42	2.20e-04	51	171	4	EFO_1001155
Disease	autism spectrum disorder (implicated_via_orthology)	NRCAM NLGN4Y MEF2A TAOK2 CNTNAP5 NLGN4X	2.68e-04	152	171	6	DOID:0060041 (implicated_via_orthology)
Disease	Warburton Anyane Yeboa syndrome	TRIP13 BUB3	3.30e-04	5	171	2	C2931286
Disease	Mosaic variegated aneuploidy syndrome 1	TRIP13 BUB3	3.30e-04	5	171	2	C1850343
Disease	urate measurement, spine bone mineral density	PAPPA2 SH3TC2 EGFR RIC1	3.62e-04	58	171	4	EFO_0004531, EFO_0007701
Disease	low affinity immunoglobulin gamma Fc region receptor II-b measurement	FCGR2C FCGR2A FCGR2B	4.00e-04	25	171	3	EFO_0021970
Disease	apolipoprotein A 1 measurement	PAPPA2 COL7A1 ARHGEF28 PKD1L3 ADAR CEP164 TAOK2 IRF9 BMP7 FZR1 CELSR2 FCGR2B CYP26C1 PLA2G6	4.46e-04	848	171	14	EFO_0004614
Disease	SYSTEMIC LUPUS ERYTHEMATOSUS	FCGR2A FCGR2B	4.93e-04	6	171	2	152700
Disease	LDL cholesterol change measurement	PKD1L3 CELSR2	6.88e-04	7	171	2	EFO_0007804
Disease	low affinity immunoglobulin gamma Fc region receptor II-a/b measurement	FCGR2A FCGR2B	6.88e-04	7	171	2	EFO_0008211
Disease	lymphoid leukemia (is_implicated_in)	FCGR2A FCGR2B	6.88e-04	7	171	2	DOID:1037 (is_implicated_in)
Disease	central nervous system cancer	PAPPA2 EGFR C12orf42	7.63e-04	31	171	3	EFO_0000326
Disease	Squamous cell carcinoma of lung	ANKK1 MAST4 EGFR	8.38e-04	32	171	3	C0149782
Disease	neutropenia (is_implicated_in)	FCGR2A C5	9.14e-04	8	171	2	DOID:1227 (is_implicated_in)
Disease	excessive daytime sleepiness measurement	TMEM132B ASB3 PATJ	9.18e-04	33	171	3	EFO_0007875
Disease	coronary aneurysm	CAMK1D CSMD2 CSMD1	1.09e-03	35	171	3	EFO_1000881
Disease	ovarian neoplasm	RNF43 EGFR SULF1 MLH1 WDR77	1.13e-03	134	171	5	C0919267
Disease	plexin-B2 measurement	FCGR2C FCGR2B	1.17e-03	9	171	2	EFO_0021867
Disease	Malignant neoplasm of ovary	RNF43 EGFR SULF1 MLH1 WDR77	1.24e-03	137	171	5	C1140680
Disease	serum non-albumin protein measurement	TBKBP1 CARMIL2 UGT3A1 DNAH2 FCGR2C FCGR2A FCGR2B MAP3K19	1.27e-03	361	171	8	EFO_0004568
Disease	Ankylosing spondylitis	TBKBP1 IL1R2	1.77e-03	11	171	2	C0038013
Disease	Systemic lupus erythematosus	FCGR2A FCGR2B	1.77e-03	11	171	2	cv:C0024141
Disease	ankylosing spondylitis	TBKBP1 FCGR2A IL1R2 CSMD1	1.97e-03	91	171	4	EFO_0003898
Disease	systemic lupus erythematosus (implicated_via_orthology)	FCGR2C FCGR2A FCGR2B	1.99e-03	43	171	3	DOID:9074 (implicated_via_orthology)
Disease	immunoglobulin isotype switching measurement	UBR4 KLRC2 KLRC3	2.13e-03	44	171	3	EFO_0010128
Disease	childhood trauma measurement, smoking behaviour measurement	PAPPA2 ERMP1 RIC1	2.27e-03	45	171	3	EFO_0005671, EFO_0007979
Disease	hematocrit	DNAH2 GPATCH2 DGKD BCL11A RNF43 CEP164 PLEKHG1 FCGR2C FCGR2A FCGR2B TBK1 ASB3 MAP3K19 PSD4	2.36e-03	1011	171	14	EFO_0004348
Disease	Adenocarcinoma of large intestine	RNF43 EGFR TBK1 MLH1	2.39e-03	96	171	4	C1319315
Disease	S-warfarin measurement	TTI2 NHSL1 EGFR ZNF534	2.48e-03	97	171	4	EFO_0803323
Disease	Colorectal Carcinoma	COL7A1 NRCAM LRRC4 CSMD3 RNF43 LIG3 SIGLEC7 NLGN4X EGFR TENM1 MLH1	2.73e-03	702	171	11	C0009402
Disease	Alzheimer disease, dementia, family history of Alzheimer’s disease	KCNH8 ASB3 DNAI2	2.73e-03	48	171	3	EFO_0009268, MONDO_0001627, MONDO_0004975
Disease	glycodeoxycholate measurement	COL7A1 CSMD1	2.90e-03	14	171	2	EFO_0010493
Disease	glucose-dependent insulinotropic peptide measurement, glucose tolerance test	PAPPA2 ARHGEF17	2.90e-03	14	171	2	EFO_0004307, EFO_0008464
Disease	risky sexual behaviour measurement	POU3F2 BCL11A PKD1L3 TENM2 KPNA2	3.11e-03	169	171	5	EFO_0007877
Disease	autoimmune thrombocytopenic purpura (is_implicated_in)	FCGR2A FCGR2B	3.34e-03	15	171	2	DOID:8924 (is_implicated_in)
Disease	low density lipoprotein cholesterol measurement, response to selective serotonin reuptake inhibitor	CSMD2 USP6NL	3.34e-03	15	171	2	EFO_0004611, EFO_0005658
Disease	Inherited oocyte maturation defect	TRIP13 WEE2	3.80e-03	16	171	2	cv:CN238505
Disease	Malaria, susceptibility to	FCGR2A FCGR2B	3.80e-03	16	171	2	cv:C1970028
Disease	–	FCGR2A FCGR2B	3.80e-03	16	171	2	611162
Disease	peripheral arterial disease	CSMD3 CELSR2 KPNA2	3.82e-03	54	171	3	EFO_0004265
Disease	phosphatidylcholine 40:6 measurement	TMTC4 CSMD1	4.29e-03	17	171	2	EFO_0010389
Disease	Amyotrophic Lateral Sclerosis	ARHGEF28 CAMK1G TBK1	4.67e-03	58	171	3	C0002736
Disease	Malignant neoplasm of endometrium	EGFR MLH1	4.81e-03	18	171	2	C0007103
Disease	Carcinoma in situ of endometrium	EGFR MLH1	4.81e-03	18	171	2	C0346191
Disease	laryngeal squamous cell carcinoma (is_marker_for)	EGFR MLH1	5.35e-03	19	171	2	DOID:2876 (is_marker_for)
Disease	anorectal malformation	CSMD2 THBS2	5.35e-03	19	171	2	MONDO_0019938

Protein segments in the cluster

Peptide	Gene	Start	Entry
QGHNLTEDARHPESW	ELL3	126	Q9HB65
HGAQVNGVTADWHTP	ASB9	91	Q96DX5
LVCERNHQWNHALPS	CSMD1	911	Q96PZ7
LTCQHGTNRNWDHPL	CSMD2	2161	Q7Z408
ALTCLHGVSRNWNHP	CSMD3	2261	Q7Z407
WLDSHHRELQAGTPL	HAAO	186	P46952
WVPSQDTHHTQELLA	BRICD5	151	Q6PL45
RHEISPGHDGTWNDN	ATG16L1	66	Q676U5
SSPSHHWQLGQKLEG	CARMIL2	781	Q6F5E8
NWTPLHLAARHGEEA	ANKK1	626	Q8NFD2
HARNKVGWTPAHLAA	ANKK1	686	Q8NFD2
DSIQWFHNGNLIPTH	FCGR2A	71	P12318
SIQWFHNGNLIPTHT	FCGR2B	81	P31994
DPTHAWSGGLDHQLK	BUB3	66	O43684
LAVHIAHSLRNSPDW	AARSD1	296	Q9BTE6
LTLWDQLGDGTPQHH	DOP1A	876	Q5JWR5
GANSIWEHSLLDPAQ	GIT1	71	Q9Y2X7
SVDHGQWLDTPLHAA	ASB11	221	Q8WXH4
PQHFLGSSLVAWHGL	CELSR2	1616	Q9HCU4
GDLNTAHRPIDHWDA	APEX2	196	Q9UBZ4
FLLLQASDGIHHWTP	NUDT2	26	P50583
VHPSSVNRDLQTHGW	DHX29	1256	Q7Z478
IKRAATHLSWHPDGN	DNAI2	161	Q9GZS0
THLSWHPDGNRKLAV	DNAI2	166	Q9GZS0
TSNHWVVNPRHNLGL	BMP7	231	P18075
QASHGFITQHPWASL	ERMP1	256	Q7Z2K6
SAVASLAAAWPQLHQ	BAZ1A	521	Q9NRL2
HWTDAGQLTPALLHS	RAVER1	206	Q8IY67
QSWLSNIGPTHHEID	RIC1	1171	Q4ADV7
FLLSWSGPLQGQQHH	OLFML3	11	Q9NRN5
HWNLSTGVLHQRESP	KIAA1107	721	Q9UPP5
LWTAAGSGHQILPFH	ARHGEF28	1626	Q8N1W1
ADGLHSWHIFSQPQA	ARHGEF17	211	Q96PE2
SPGNWGHLDQLAALH	CES1P1	186	Q9UKY3
ARQEVDHHWQASGGP	MAPKAPK3	81	Q16644
SHLQDPNHLTLDWVA	KCTD21	176	Q4G0X4
LVPAGDHWHLSDLGQ	MAPK8IP3	226	Q9UPT6
PGLWHHQTEVSGTQT	NRCAM	691	Q92823
PHLANATLETEWFHG	GPR158	211	Q5T848
LPALWFHHVQQSQGC	JMJD7	271	P0C870
TLSWHHEGLPVAESN	HMCN2	1656	Q8NDA2
SAWFLLQHAQNTHGL	BCL11A	181	Q9H165
PGRHWNEGHATILSQ	NHSL1	471	Q5SYE7
SIQWFHNGNLIPTHT	FCGR2C	81	P31995
AGWNHDSTHVIRFPL	KCTD1	181	Q719H9
SSSPNLELHHNFRWV	NAV3	2161	Q8IVL0
SHIWIFAHVTQGQDP	FRYL	786	O94915
NWHSPLHSTGVDVDL	DDHD2	271	O94830
LVHQGAAHAGAAWAQ	POU3F1	116	Q03052
HPWQVALLSGNQLHC	KLK7	41	P49862
QINHPFVHSLGDSWQ	RSKR	161	Q96LW2
HLVQSDGTVPFWAHA	LMAN1	56	P49257
KPAHGAHWTENSLGN	LRRC4	611	Q9HBW1
AHWTENSLGNSLHPT	LRRC4	616	Q9HBW1
AWQQHHLGQAALSSL	MEF2A	366	Q02078
GPHEGHWNVFLAQTL	CHRDL2	401	Q6WN34
SQWSETDLLHGHPLF	LIG3	36	P49916
PTAARHQDSWNGLSH	HSPA9	21	P38646
WLASGHTERPHLFQN	ADAMTSL5	11	Q6ZMM2
SLPHVHVALWINSQG	POLA1	1151	P09884
LHQAGEIWHISASPA	EIPR1	61	Q53HC9
ALSHPWIDGNTALHR	CAMK1G	271	Q96NX5
AANHWVLPAAEFHGL	TRIP13	121	Q15645
LASPHAHISEQAVWA	KPNA2	171	P52292
GVAAVHAWHLLGDQT	POMT1	216	Q9Y6A1
HAWHLLGDQTLSNVG	POMT1	221	Q9Y6A1
GPGTWHELQALQVRH	PODNL1	471	Q6PEZ8
DHQWVAPAVATADLH	NLGN4Y	446	Q8NFZ3
LVFWSTALPQSHFQH	PAPPA2	426	Q9BXP8
AAVKAIAWSPHQHGL	FZR1	356	Q9UM11
HWAQKGSHQISLDNP	EGFR	1156	P00533
SWQLPIHAAAQMGHT	ASB3	246	Q9Y575
LHGHPSKWINQASDE	CD101	916	Q93033
GQRDHLPHSADQGTW	BRME1	511	Q0VDD7
QAWNQHSGVVRPDSH	ADAR	251	P55265
TLSIASEHHNQPLWL	CACNA1S	446	Q13698
LVTNPHTDAWKSHGL	GADD45B	121	O75293
VRQHGHPQWLSAGQT	ATG9A	526	Q7Z3C6
ETGNHWNIFHSDPLI	C5	1026	P01031
LSQLLQPEGHHWETQ	IL23A	131	Q9NPF7
NQDHPDAWSLIGNLH	CTR9	561	Q6PD62
LTERWAQGHPAIHFS	DHRS12	211	A0PJE2
PAGEHWLGNEVVHQL	ANGPT4	356	Q9Y264
QWPQSAHILLGSHTL	CYP26C1	116	Q6V0L0
HHIVWNVEEGSPACQ	MAST4	1171	O15021
NKEAHSSLGAPVHLW	DGKD	1131	Q16760
HQLDTDLFPHLGLDW	INO80D	311	Q53TQ3
FWEESHGSSHTPQNL	IRF9	351	Q00978
GVHTSWNQGLPSIQH	KLF17	46	Q5JT82
ASWVGNHVSPAHRQA	LINC02913	146	Q8NAJ2
RVSWHSAHGPEKSQL	COL7A1	716	Q02388
HTDELWGLCTHPSQN	EML3	596	Q32P44
FRGQDAWDPHTHVLL	CELSR3	2351	Q9NYQ7
WFSPGARTEHDQHQL	GPATCH2	391	Q9NW75
NTGWPESIRNHFASH	DNAH2	186	Q9P225
ANFSHQDVWLEAHLP	SLC22A7	56	Q9Y694
DHQWVAPAVATADLH	NLGN4X	446	Q8N0W4
LGPLDHHWLVENNIS	CNOT6	506	Q9ULM6
LQEWAQAHAVSHPNE	MAP3K19	111	Q56UN5
PSATLGSLLDDQHWH	CNTNAP5	256	Q8WYK1
QLGLNAEHAWADAPI	CPT1B	466	Q92523
LQFHAGQAWVPTTHR	DPPA2	241	Q7Z7J5
SPLNHSLLTTVGWDH	WDR77	306	Q9BQA1
LQGAHAWILQVPSEH	PRSS56	486	P0CW18
AHNGSLQHLTWLGLQ	RGPD1	421	P0DJD0
PGDSHLQWQLNLLTH	PHF20L1	936	A8MW92
LQHHVPSDLEGTEQW	FAM180B	86	Q6P0A1
HIDLQPWAGSAQSLD	METTL24	111	Q5JXM2
SHSEEHIPTQQGLAW	RTTN	1356	Q86VV8
HLGARASGQPLQHWA	SYT8	346	Q8NBV8
FAVSEQGNIPHSHDW	TMEM132B	931	Q14DG7
FRNSSHHPWVTINGL	KLRC2	176	P26717
AIQAHNGSLQHLTWL	RGPD2	426	P0DJD1
HSSVLAGNSQEQWHP	KCP	41	Q6ZWJ8
ALASVGQLHLAWHEG	NCAN	286	O14594
VAGQLLPSTWSLHAH	FAM120AOS	201	Q5T036
QLQHHSSGILPKWTL	PSD4	471	Q8NDX1
LHSLRLWHDNSGVSP	PKD1L3	806	Q7Z443
WGLSHLQSTSQHPAA	RNF43	416	Q68DV7
HAQAQAHETGLPWAG	SPPL2C	651	Q8IUH8
TESWADDNPRHHGLA	SIGLEC7	411	Q9Y286
HIAQNESPVLQSGHW	TAOK2	236	Q9UL54
SVHLHNSWVLNSNIP	TENM1	241	Q9UKZ4
WSLNKHHILNPQSGI	TENM1	1136	Q9UKZ4
NLGHLSLKSWAQHPA	SH3TC2	881	Q8TF17
LDPSNLGGWSLDKHH	TENM2	1171	Q9NT68
VFRNSSHHPWVTING	KLRC3	176	Q07444
NHPSWSVAHLAVELG	PLA2G6	116	O60733
HNHSFVGCVNPQWAL	MLH1	526	P40692
SWDFLGHPLKNHNSL	CYB5R4	251	Q7L1T6
NGHPLSHAHQWITAL	POU3F2	51	P20265
NCPSVNDGRWHHIAI	SVEP1	1501	Q4LDE5
DGLTVLWPHHQDFQS	IL1R2	381	P27930
HPWIAGDTALNKNIH	CAMK1D	276	Q8IU85
HASVAGQHPLDWLLT	BRINP2	46	Q9C0B6
TPLHLAAEHAWQDIA	ANKDD1A	326	Q495B1
SHNVWHLLSAEGVAL	CEP164	1096	Q9UPV0
TPQLEAWIHNITHGS	CHST6	296	Q9GZX3
VRFWHLGEPNHSAEQ	CLEC6A	161	Q6EIG7
WAHSVNPVHLEAQGI	C12orf42	176	Q96LP6
ASDHANQLSIHIPGW	C10orf90	396	Q96M02
EGSATLHHWQQLAQP	TRAK1	581	Q9UPV9
HWHQRCQPSDATNGL	SLC35G4	26	P0C7Q5
LQAETPLGDLWHHDF	TMTC4	56	Q5T4D3
AHLPQGVIWTCQSSH	UGT3A1	321	Q6NUS8
ELQSWGVHHLSNGQR	USP6NL	376	Q92738
GQWFHISDTHVQAVP	USP16	791	Q9Y5T5
HQNTPLHWAVAAGNV	ZDHHC13	216	Q8IUH4
LLPHSVVQWNVGSHQ	NDUFAF3	81	Q9BU61
KNSLVGPAWQTGLHH	TTI2	131	Q6NXR4
LVHSNRWNSHGPSLL	PLCXD2	286	Q0VAA5
PSVNELHFGTQWLHD	PATJ	901	Q8NI35
LHFGTQWLHDNEPSE	PATJ	906	Q8NI35
GGTSQLHHVDVWPLN	SLC12A9	716	Q9BXP2
HLDFGSSLEQPQGHW	ZNF620	126	Q6ZNG0
QHGLTLQLHLTEWQP	ZNF534	121	Q76KX8
ISSGHLELEWQHPSS	MPL	401	P40238
VDFWGNHLTQSHPEV	ZNF518A	576	Q6AHZ1
TQIIAGDRPDNHWLH	PSME4	1236	Q14997
AAHPNSIFLIDHAWT	TTLL12	111	Q14166
NPIGSLQELAIHHGW	PRKRA	126	O75569
TPEQHGTWGNRHLFA	nan	621	Q3C1V9
DIGAVQWNPHDSFAH	WDR59	61	Q6PJI9
LLLPDDWGQHSEHQV	ZCCHC4	131	Q9H5U6
HGAPVLFQNLSGVHW	ZKSCAN2	486	Q63HK3
WLHHDPDGVLTLNAE	ZNF236	11	Q9UL36
ESLPTNGAAWHHIRK	WEE2	431	P0C1S8
WLPGLAQHQKSHSAE	ZNF597	251	Q96LX8
VSPSQVHHGSGDWLL	PLEKHG1	1071	Q9ULL1
PHLHNGWQVDQAILS	TXNL4A	6	P83876
EHLRNALWHTGNTPG	THBS2	1076	P35442
LAWHPLGHILCSGSN	WDR33	381	Q9C0J8
HPIHGLAWTDGNQVV	WDCP	21	Q9H6R7
AGHLQLHNAAVDWLS	UBR4	1551	Q5T4S7
LPGLTCFTHDNNHWQ	SULF1	741	Q8IWU6
AHAEHAQSWPSINLL	TBKBP1	561	A7MCY6
IQVWSLQQGHPLHSF	WDR87	226	Q6ZQQ6
SLADAWAHQEGTHPK	TBK1	531	Q9UHD2
HGWDQESSLHESNPL	ZKSCAN8	31	Q15776
LPSLQHSQHSEWPDA	GARIN5B	906	Q8N5Q1
LHSPHQNVCEQAVWA	KPNA4	166	O00629
TSWSAHQPCLHLQTG	KCNH8	926	Q96L42
PEVVNRQGHSHSADW	RPS6KA1	231	Q15418
HNPAGTSVQNMLHWA	LIPK	281	Q5VXJ0
NWKLILHGTSSQPEH	PCSK1	586	P29120